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andcolleagues also seem to imply that an apparent di¡er-
ence at baseline in nights without awakenings was
causing the observed di¡erence in exacerbations.
Nights without awakenings was only one variable in-
cluded in the de¢nition of a mild exacerbation, not
the sole one, and the apparent di¡erence in baseline
medianswas an artefactof the data as shown in the table
below. The centiles above and below the 50th and 51st
clearly show the similarity between the two groups at
baseline:TABLE 1
Percentage of nightswithno awakenings
at baseline
Percentile of values Seretide 250 Bud 800 + Form12
45th 14.3 14.3
46th 14.3 14.3
47th 14.3 14.3
48th 14.3 14.3
49th 14.3 14.3
50th 28.6 16.7
51st 28.6 16.7
52nd 28.6 28.6
53rd 28.6 28.6
54th 28.6 28.6The di¡erences on treatment were signi¢cant over
Months1and 2 and over the whole of treatment, which
is statistically the most robust measure. Month 3 only
just failed to reach signi¢cance due to the reduced
amountof diarycarddata available for analysis, but there
was still a clear trend in favour of Seretide (median 89.3%
on Seretide vs 71.4% on Bud+Form).We therefore do not
agree thatboth groupswere comparable after 3months.
Strati¢cation of exacerbations by baseline was an en-
tirely appropriateway to allow for the apparent (though
not real) baseline di¡erence in awakenings. In other
settings, other valid approaches may be available but
the method proposed by Dr Selroos and colleagues is in
this instance not possible as the run-in baselinewas only
2weeks and so too short to provide robustdata for such
an analysis.We therefore stand by the method and con-
clusions presented in our paper.
Our study was of robust randomised, double blind,
double dummy design, and analysed to the highest inter-
national standards. It re£ects clinical reality in terms of
the increase in treatment of symptomatic moderate-se-
vere asthma patients. Seretide 50/250mg was at least as
good as budesonide 800mg + formoterol 12mg in all thedoi:10.1053/rmed.2003.1512
Dear Sir,
We thank Drs Selroos, Ekstr˛m and Hultquist for
their comments but disagree with their interpretation
in a number of important ways.
Atbaseline thesepatientswithmoderate-severe asth-
ma were still symptomatic on 1000-1600mg/day of BDP
equivalent and so clearly required more treatment.
Treatment with budesonide 1600mg/day (a licensed dose
for asthma) plus formoterol 24mg/day was thus not un-
reasonable and forquite a numberofpatients entailedno
increase in their steroid dose.We therefore do not feel
that the dosewas excessivelyhigh. Also,while themajor-
ity of overall costs were indeed due to study drug acqui-
sition, hospital costs were also a key factor, at 21% of
total costs in the Bud+Form group. Therefore, any re-
duction in drug costs of budesonide would not o¡set
these high hospital costs.
Dr Selroos and colleagues speculate that a di¡erence
in compliancemighthave accounted for the observeddif-
ferences between treatments. As this was a double-
dummy study both groups received the same number
and types of inhalers, and at each dosing occasion pa-
tientswere required to inhale ¢rst from theDiskus, then
the Turbuhalers, with no more than 2 minutes
between each inhaler. The formoterol inhaler would
thus have been the second or third in order and
there would have been no time for any e¡ects to be no-
ticed before all inhalers were taken. The patients
would therefore not have known which was producing
the bene¢t and would have no incentive to miss
taking one or more of the inhalers. We therefore
reject the claim that the study was biased due to bude-
sonide compliance being reduced, particularly as similar
issues were apparently not a problem with another bu-
desonide plus formoterol study using a double-dummy
design (1).
The aims of asthma management in the Global Initia-
tive for Asthma (GINA) guidelines include minimal,
ideally no, chronic symptoms, including nocturnal symp-
toms, therefore, all grades of exacerbation reported in
our study should be considered clinically relevant (2).
The de¢nition of a mild exacerbation includes43 addi-
tional reliever inhalations in 24 hours andwaking at night
due to asthma 2 consecutive nights. Such situations
indicate improperly controlled asthma requiring an in-
crease in therapy according to the GINA guidelines.
This is true for patients with more severe asthma as
well as those with milder disease and is therefore of
448 RESPIRATORYMEDICINEendpoints examined and was superior in a number of
clinically important endpoints.
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